Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632110 | 0.84 | IDO1 (0.58) | IDO1TDO2 | |
| SCHEMBL4983598 | 0.84 | TP53 (0.46) | BCHEACHEBACE1MEN1KMT2A | |
| SCHEMBL4983588 | 0.84 | TP53 (0.46) | BCHEACHEBACE1MEN1KMT2A | |
| SCHEMBL5631279 | 0.82 | IDO1 (0.55) | IDO1TDO2 | |
| SCHEMBL4992741 | 0.81 | IDO1 (0.61) | IDO1TDO2 | |
| SCHEMBL5630345 | 0.81 | IDO1 (0.61) | IDO1TDO2 | |
| SCHEMBL4986046 | 0.81 | IDO1 (0.60) | IDO1TDO2 | |
| SCHEMBL5657325 | 0.79 | IDO1 (0.58) | IDO1TDO2 | |
| SCHEMBL5632339 | 0.79 | IDO1 (0.58) | IDO1TDO2 | |
| SCHEMBL5631289 | 0.79 | IDO1 (0.53) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | claimed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | claimed |
| EP-1971583-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | claimed |
| WO-2007075598-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | IDO1 1/4885TDO2 13/4885BCHE 101/4885 |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | IDO1 1/4885TDO2 13/4885BCHE 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.